can someone critique these numbers - looks too goo, page-3

Haven't looked specifically at your figures, although at a glance they look ok, however, I would also consider that there are 25.5mill listed and unlisted options out there. Most have very favourable strike prices, so you can probably assume they will all be exercised.

So based on your calculations SLT is currently fully-priced for Hep A & Hep E, making Hep C the wild-card. The company is also fast-tracking other projects such as VLP.

Cheers